Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Commercial Officer | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,472 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Tax withholding · Disposed 2,318 · Balance 42,472 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 21, 2026 22:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,318 | $50.20 | $116,363.60 |
DisclosureSEC source: 0001628280-26-037455 · wk-form4_1779401100.xml · nonDerivative · entry 1 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,472 Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 17:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,245 | $56.05 | $69,782.25 |
DisclosureSEC source: 0001628280-26-019269 · wk-form4_1773855732.xml · nonDerivative · entry 2 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,790 Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 17:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 36,680 | $0.00 Strike: $57.43 | $0.00 |
DisclosureSEC source: 0001628280-26-019269 · wk-form4_1773855732.xml · derivative · entry 3 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,680 Underlying: Common Stock · 36,680 shares Expires 2036-03-15 F2 · derivative.exercise_date: Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 17:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 15,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-019269 · wk-form4_1773855732.xml · nonDerivative · entry 1 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,035 F1 · price: Restricted stock units granted March 16, 2026. Price not applicable. Read SEC document |
| October 31, 2025 Filed Feb 13, 2026 23:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 80 | $45.54 | $3,642.80 |
DisclosureSEC source: 0001628280-26-008231 · wk-form5_1771027100.xml · nonDerivative · entry 1 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,625 F1 · date: Represents the shares acquired by the reporting person on October 31, 2025, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:02 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,155 | $59.93 | $129,149.15 |
DisclosureSEC source: 0001048477-25-000080 · wk-form4_1747947769.xml · nonDerivative · entry 1 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,545 Read SEC document |
| May 02, 2025 Filed May 6, 2025 21:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 273 | $64.92 | $17,723.16 |
DisclosureSEC source: 0001048477-25-000053 · wk-form4_1746565636.xml · nonDerivative · entry 2 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,700 F2 · date: Trade made pursuant to a 10b5-1 plan executed on September 13, 2024. Read SEC document |
| April 30, 2025 Filed May 6, 2025 21:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 273 | $54.14 | $14,779.40 |
DisclosureSEC source: 0001048477-25-000053 · wk-form4_1746565636.xml · nonDerivative · entry 1 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,973 F1 · date: Represents the shares acquired by the reporting person on April 30, 2025, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 22:25 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 30,880 | $0.00 Strike: $71.55 | $0.00 |
DisclosureSEC source: 0001048477-25-000035 · wk-form4_1742336744.xml · derivative · entry 2 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,880 Underlying: Common Stock · 30,880 shares Expires 2035-03-16 F2 · derivative.exercise_date: Option grant vests 12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 22:25 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 13,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000035 · wk-form4_1742336744.xml · nonDerivative · entry 1 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,700 F1 · price: Restricted stock units granted March 17, 2025. Price not applicable. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:36 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 33,520 | $0.00 Strike: $77.05 | $0.00 |
DisclosureSEC source: 0001048477-24-000090 · wk-form4_1716410173.xml · derivative · entry 3 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,520 Underlying: Common Stock · 33,520 shares Expires 2034-05-19 F2 · derivative.exercise_date: Option grant vests 12/48th on May 20, 2025 and 1/48th on the 1st day of each month thereafter. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:36 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000090 · wk-form4_1716410173.xml · nonDerivative · entry 2 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,390 F1 · price: Restricted stock units granted on May 20, 2024. Price not applicable. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:36 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 14,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000090 · wk-form4_1716410173.xml · nonDerivative · entry 1 Hubbard Cristin · CIK 0002021836 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,690 F1 · price: Restricted stock units granted on May 20, 2024. Price not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.